Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
|
CUREVAC N.V.
|
|
(Name of Issuer)
|
|
Common Shares € 0.12 par value
|
|
(Title of Class of Securities)
|
N2451R105
(CUSIP Number)
Scott Sonnenblick
Linklaters LLP
1345 Avenue of the Americas
New York, NY
|
+1 212 903 9292
|
|
(Name, Address and Telephone Number of Persons Authorized to Receive Notices and Communications)
|
|
January 28, 2021
|
|
(Date of Event Which Requires Filing of This Statement)
|
If the filing person has previously filed a
statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
| * |
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page
|
The information required on this cover page shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Act"),
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No.
|
N2451R105
|
13D
|
Page
|
2 |
of
|
4
|
Pages
|
|
1
|
NAMES OF REPORTING PERSONS
|
|
|
||
| KfW |
|
|
|||
|
|
|
||||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☒
|
||
|
(b)
|
☐
|
||||
|
|
|
||||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
SOURCE OF FUNDS (SEE INSTRUCTIONS)
|
|
|
||
| OO |
|
|
|||
|
|
|
||||
|
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
| Germany |
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
|
29,871,441*
|
|
|
|||
|
|
|
||||
|
8
|
SHARED VOTING POWER
|
|
|
||
|
117,390,408**
|
|
|
|||
|
|
|
||||
|
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
29,871,441*
|
|
|
|||
|
|
|
||||
|
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
117,390,408**
|
|
|
|||
|
|
|
||||
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
117,390,408**
|
|
|
|||
|
|
|
||||
|
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
|
63.1%***
|
|
|
|||
|
|
|
||||
|
14
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
||
| OO |
|
|
|||
|
|
|
||||
* See Item 5 of the Statement of Beneficial Ownership on Schedule 13D (No. 005-91630) filed by
KfW with the Securities and Exchange Commission (the “SEC”)
on August 24, 2020 (the “Schedule 13D”).
** Based on the 29,871,441 common shares of CureVac N.V. (the “Issuer”) held by KfW and
87,518,967 common shares of CureVac N.V. beneficially owned by Dievini Hopp BioTech holding GmbH & Co. KG (“dievini”) and Dietmar Hopp (“Hopp”), pursuant to the Shareholders’ Agreement dated as of June 16, 2020 and by and among KfW, dievini and Hopp (the “Shareholders’ Agreement”) and as set forth in the Statement of Beneficial Ownership on Schedule 13D (No. 005-91630) filed by dievini, DH-LT-Investments
GmbH, DH-Capital GmbH & Co. KG, OH Beteiligungen GmbH & Co. KG, Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach, Prof. Dr. Christof Hettich, Dr. Mathias Hothum with the SEC on August 24, 2020.
*** Based on 186,163,480 common shares of CureVac N.V. outstanding as set forth in the
prospectus on Form F-1 of CureVac N.V. (No. 333-252391) filed with the SEC on January 25, 2021.
|
CUSIP No.
|
N2451R105
|
13D
|
Page
|
3 |
of
|
4
|
Pages
|
This Amendment No. 1 to the Schedule 13D (the “Amendment No.1”) amends
and supplements the Schedule 13D to account for the offer of 5,000,000 common shares of CureVac N.V. Except as amended and supplemented by this Amendment No.1, the Schedule 13D remains unchanged.
|
Item 5.
|
Interest in Securities of the Issuer.
|
| (a) |
After the consummation of the offering as of January 28, 2021, the Reporting Person has sole voting
and dispositive power over 29,871,441 Common Shares, representing 16.0% of the outstanding Common Shares.
|
| (b) |
Pursuant to the Shareholders’ Agreement, as disclosed by Item 6 of the Schedule 13D, the Reporting Person has shared voting and dispositive power with dievini and
Hopp over 117,390,408 Common Shares, representing 63.1% of the outstanding Common Shares.
|
|
Item 7.
|
Materials to be Filed as Exhibits.
|
|
Exhibit No.
|
Description
|
|
|
1
|
|
|
|
2
|
Investment and Shareholders’ Agreement dated as of July 17, 2020, by and among
CureVac AG and several shareholders. (Incorporated herein by reference from Exhibit 3.5 of CureVac N.V.’s prospectus on Form F-1 of CureVac N.V. (No. 333-240076) filed with the SEC on August 10, 2020.)
|
|
|
3
|
Relationship Agreement dated as of July 17, 2020, by and among KfW, Dievini Hopp
BioTech holding GmbH & Co KG and Dietmar Hopp, dated July 17, 2020. (Incorporated herein by reference from Exhibit 3.7 of CureVac N.V.’s prospectus on Form F-1 of CureVac N.V. (No. 333-240076)
filed with the SEC on August 10, 2020.)
|
|
|
4
|
Form of Registration Rights Agreement dated as of August 14, 2020, by and among
KfW, dievini and DH-LT-Investments GmbH. (Incorporated herein by reference from Exhibit 4.1 of CureVac N.V.’s prospectus on Form F-1 of CureVac N.V. (No. 333-240076) filed with the SEC on August 10,
2020.)
|
|
|
5
|
Supplement to the Shareholders’ Agreement (Exhibit No. 1) dated as of August 14, 2020, by and among KfW, Dievini Hopp BioTech holding GmbH &
Co KG, Dietmar Hopp and DH-LT Investments GmbH. (Incorporated herein by reference from Exhibit 5 of the Statement of Beneficial Ownership on Schedule 13D (No. 005-91630) filed by KfW on August 24, 2020.)
|
|
CUSIP No.
|
N2451R105
|
13D
|
Page
|
4 |
of
|
4
|
Pages
|
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in
this statement is true, complete and correct.
Dated: January 29, 2021
|
KfW
|
||
|
By:
|
/s/ Reichhelm
|
|
|
Name: Nils Reichhelm
|
||
|
Title: Abteilungsdirektor
|
||
|
By:
|
/s/ Pradkhan
|
|
|
Name: Elina Pradkhan
|
||
|
Title: Senior Manager
|
||
ANNEX A
The following sets forth the name, position, principal occupation and citizenship of each member of the executive board of KfW as
set forth on the website of KfW as of January 29, 2021.
EXECUTIVE BOARD
|
Name
|
Principal Occupation or Employment
|
Business Address
|
Citizenship
|
|||
|
Dr Günther Bräunig
|
Chief Executive Officer of KfW
|
(1)
|
Germany
|
|||
|
Dr Ingrid Hengster
|
Member of the Executive Board of KfW
|
(1)
|
Austria
|
|||
|
Melanie Kehr
|
CIO of KfW
|
(1)
|
Germany
|
|||
|
Bernd Loewen
|
CFO of KfW
|
(1)
|
Germany
|
|||
|
Dr Stefan Peiß
|
CRO of KfW
|
(1)
|
Germany
|
| (1) |
Palmengartenstrasse 5-9, 60325 Frankfurt am Main, Germany
|
Exhibit Index
|
Exhibit No.
|
Description
|
|
|
1
|
Shareholders’ Agreement dated as of June 16, 2020, by and among KfW, Dievini Hopp
BioTech holding GmbH & Co KG and Dietmar Hopp. (Incorporated herein by reference from Exhibit 3.6 of CureVac N.V.’s prospectus on Form F-1 of CureVac N.V. (No. 333-240076) filed with the SEC on
August 10, 2020.)
|
|
|
2
|
Investment and Shareholders’ Agreement dated as of July 17, 2020, by and among
CureVac AG and several shareholders. (Incorporated herein by reference from Exhibit 3.5 of CureVac N.V.’s prospectus on Form F-1 of CureVac N.V. (No. 333-240076) filed with the SEC on August 10,
2020.)
|
|
|
3
|
Relationship Agreement dated as of July 17, 2020, by and among KfW, Dievini Hopp
BioTech holding GmbH & Co KG and Dietmar Hopp, dated July 17, 2020. (Incorporated herein by reference from Exhibit 3.7 of CureVac N.V.’s prospectus on Form F-1 of CureVac N.V. (No. 333-240076)
filed with the SEC on August 10, 2020.)
|
|
|
4
|
Form of Registration Rights Agreement dated as of August 14, 2020, by and among
KfW, dievini and DH-LT-Investments GmbH. (Incorporated herein by reference from Exhibit 4.1 of CureVac N.V.’s prospectus on Form F-1 of CureVac N.V. (No. 333-240076) filed with the SEC on August 10,
2020.)
|
|
|
5
|
Supplement to the Shareholders’ Agreement (Exhibit No. 1) dated as of August 14, 2020, by and among KfW, Dievini Hopp BioTech holding GmbH &
Co KG, Dietmar Hopp and DH-LT Investments GmbH. (Incorporated herein by reference from Exhibit 5 of the Statement of Beneficial Ownership on Schedule 13D (No. 005-91630) filed by KfW on August 24, 2020.)
|